Dr Lal Pathlabs
Dr Lal Pathlabs Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
The company expects revenue growth in the mid-teens for the fiscal year, with a possibility of higher growth leaning towards mid-teens rather than early teens after a strong Q1 performance. The company delivered a strong Q1 FY27 performance with Profit After Tax (PAT) growing 27.2% to Rs.
From Dr Lal Pathlabs's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- The company expects revenue growth in the mid-teens for the fiscal year, with a possibility of higher growth leaning towards mid-teens rather than early teens after a strong Q1 performance.
- Patient volume growth guidance is around 6%-7%, with Q1 patient volume growth ahead at 8%, but the company awaits more data post Q2 for better clarity.
- Swasthfit segment is expected to sustain high teens growth (~20%), expanding acceptance in Tier 2 and Tier 3 geographies.
- Growth is broad-based across geographies, including Delhi NCR, West India (especially Suburban), and rural outreach programs in 7 states.
2 more points from Dr Lal Pathlabs's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Dr Lal Pathlabs said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Majority of cash utilization will be on mergers and acquisitions (M&As), especially to expand presence in underpenetrated regions like West and South India.
- Capex for the current and next year is expected to be around Rs. 140-150 crore.
- Investments are also planned for rolling out high-end radiology centers, particularly in Delhi NCR and Tier 2 markets in North India, with plans for 3-4 new radiology centers this year.
- Focus on inorganic growth in international markets like Africa, Middle East (GCC), CIS, and Southeast Asia as a longer-term plan (3-5 years horizon).
2 more points from Dr Lal Pathlabs's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dr Lal Pathlabs said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Dr Lal Pathlabs's call on order book
Pro opens every point from 15K+ earnings calls
Dr Lal Pathlabs — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹703 Cr, net profit ₹132 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dr Lal Pathlabs's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Healthcare Services this season
- Aatmaj Healthcare Ltd (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- KMC Speciality (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- 3B Blackbio (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
Arthneeti Pro · Annual
Dr Lal Pathlabs and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Dr Lal Pathlabs Q1 FY27 results?
The company expects revenue growth in the mid-teens for the fiscal year, with a possibility of higher growth leaning towards mid-teens rather than early teens after a strong Q1 performance. The company delivered a strong Q1 FY27 performance with Profit After Tax (PAT) growing 27.2% to Rs.
What is Dr Lal Pathlabs share price analysis?
Dr Lal Pathlabs currently shows a below-average growth signal. The stock trades at a P/E of 56.5 with a market cap of ₹31,794 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Lal Pathlabs planning capital expenditure?
Majority of cash utilization will be on mergers and acquisitions (M&As), especially to expand presence in underpenetrated regions like West and South India. - Capex for the current and next year is expected to be around Rs.
Keep Dr Lal Pathlabs on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.